Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
277 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03605706 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. | unknown | Phase 3 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT04679038 | A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 222 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 26, 2022 |
| clinicaltrials |
| NCT05049083 | A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects | unknown | Phase 1 | 28 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05169801 | To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC | completed | Phase 3 | 520 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 27, 2021 | clinicaltrials |
| NCT04282070 | SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 | 91 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 21, 2021 | clinicaltrials |
| NCT04973020 | A Drug-drug Interaction Study of SHR6390 on Healthy Chinese Volunteers | completed | Phase 1 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 29, 2021 | clinicaltrials |
| NCT03710265 | SHR-1701 in Metastatic or Locally Advanced Solid Tumors | unknown | Phase 1 | 206 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT04316364 | A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC | recruiting | Phase 3 | 537 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 4, 2021 | clinicaltrials |
| NCT04650633 | SHR-1701 in Patients With Recurrent/Metastatic Scchn | unknown | Phase 2 | 130 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Oct 29, 2021 | clinicaltrials |
| NCT05086822 | A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors | completed | Phase 1 | 32 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Oct 21, 2021 | clinicaltrials |
| NCT05086848 | A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors | completed | Phase 1 | 15 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Oct 21, 2021 | clinicaltrials |
| NCT04948788 | SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma | unknown | Phase 2 | 102 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 28, 2021 | clinicaltrials |
| NCT04426955 | Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer | unknown | Phase 3 | 396 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 16, 2021 | clinicaltrials |
| NCT05020925 | SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04979390 | Safety, Tolerability and Pharmacokinetics of the New Formulation SHR-1316 in Subjects With Advanced Tumors | unknown | Phase 1 | 15 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jul 28, 2021 | clinicaltrials |
| NCT04479904 | A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jun 22, 2021 | clinicaltrials |
| NCT03927456 | A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | unknown | Phase 3 | 357 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 3, 2021 | clinicaltrials |
| NCT03966898 | A Study of SHR6390 in Combination With Letrozole or Anastrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | unknown | Phase 3 | 426 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 2, 2021 | clinicaltrials |
| NCT04884009 | A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer | unknown | Phase 2 | 106 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT03722186 | Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies | suspended | Phase 1 | 128 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 22, 2021 | clinicaltrials |
| NCT03666728 | A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC | terminated | Phase 2 | 5 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 17, 2021 | clinicaltrials |
| NCT03668496 | A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC | unknown | Phase 3 | 390 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 15, 2021 | clinicaltrials |
| NCT03520478 | A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer | unknown | Phase 3 | 654 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 4 | Mar 2, 2021 | clinicaltrials |
| NCT04691063 | The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC. | unknown | Phase 3 | 486 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04603833 | A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC | unknown | Phase 2 | 150 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04342936 | Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma | unknown | Phase 3 | 56 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 8, 2021 | clinicaltrials |
| NCT03741712 | A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC | terminated | Phase 1 / Phase 2 | 9 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT04390984 | Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients | unknown | Phase 1 | 22 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 11, 2021 | clinicaltrials |
| NCT04425876 | A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer | unknown | Phase 1 | 74 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 31, 2020 | clinicaltrials |
| NCT02390947 | Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT)(FACT) | completed | Phase 3 | 543 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 22, 2020 | clinicaltrials |
| NCT04664725 | Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion | unknown | Phase 1 | 18 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 11, 2020 | clinicaltrials |
| NCT04296370 | A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation | unknown | Phase 3 | 474 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04013048 | Study to Evaluate the Mass Balance and Biotransformation of [14C]-Fluzoparib in Chinese Patients With Solid Tumor | completed | Phase 1 | 5 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 31, 2020 | clinicaltrials |
| NCT03080805 | Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE) | unknown | Phase 3 | 240 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 18, 2020 | clinicaltrials |
| NCT03363555 | SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma | unknown | Phase 2 | 97 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 18, 2020 | clinicaltrials |
| NCT03134872 | A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC | completed | Phase 3 | 419 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 9, 2020 | clinicaltrials |
| NCT02691975 | A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 197 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 13, 2020 | clinicaltrials |
| NCT04383977 | Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer | unknown | Phase 2 | 54 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | May 12, 2020 | clinicaltrials |
| NCT04203485 | Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 3 | 762 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | May 8, 2020 | clinicaltrials |
| NCT04193319 | Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects | completed | Phase 1 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 10, 2019 | clinicaltrials |
| NCT02356991 | A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) | suspended | Phase 2 | 137 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 4, 2019 | clinicaltrials |
| NCT04000295 | Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer | unknown | Phase 3 | 280 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Oct 8, 2019 | clinicaltrials |
| NCT02575651 | A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies | completed | Phase 1 | 79 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 17, 2019 | clinicaltrials |
| NCT03645876 | SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer | terminated | Phase 2 | 12 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT01392235 | Famitinib in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 58 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2019 | clinicaltrials |
| NCT01994213 | A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor | terminated | Phase 2 | 53 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 22, 2019 | clinicaltrials |
| NCT02364362 | A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 18 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 18, 2019 | clinicaltrials |
| NCT02766140 | SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer | terminated | Phase 3 | 12 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 18, 2019 | clinicaltrials |
| NCT02968485 | Phase I Study of SHR7390 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 15, 2019 | clinicaltrials |
| NCT03732508 | SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer | unknown | Phase 2 | 30 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 6, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials